Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide.

ABSTRACT:

Background

Apalutamide, an androgen receptor inhibitor, has shown good efficacy in treating prostate cancer (PCa). However, dermatological adverse events (dAEs) are common and threatening, and relevant studies in China are limited.

Methods

This was a retrospective, single-center analysis. We included PCa patients who were hospitalized and received apalutamide treatment at one comprehensive hospital in eastern China from August 2020 to March 2023. These patients were categorized into two groups for comparative analysis: those with (dAEs⁺) and without dAEs (dAEs^-) based on the presence or absence of rash or itching following apalutamide administration. Demographics, PCa clinical and treatment data were extracted from the EMRS. The clinical features of dAE

SUBMITTER: Wang Q 

PROVIDER: S-EPMC11882852 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature